PRESS RELEASE - October 20, 2000

The Company has experimentally established a relationship between cancer reversion and neurological functioning :

CONTACT:

Molecular Engines Laboratories SA
Robert AMSON
Tel: 33 1 44 64 04 64 – Fax: 33 1 44 64 04 65
Email: ramson@molecular-engines.com


MEL's scientists have discovered that Presenilin 1, a gene involved in Alzheimer's disease, is regulated by the p53 tumor suppressor gene during Cancer Reversion. These findings demonstrate that the gene Presenilin 1 is a common denominator for Cancer Reversion and Neurodegeneration. Accordingly, the genes that the Company is identifying in the field of Tumor Reversion are also potential targets in the treatment of neurological diseases such as Alzheimer's disease. Furthermore, MEL' s invention discloses another application: the p53 knock-out mice, as an animal model to study the development of tumors could also be used as an animal model to test anxiolytic drugs and drugs that could improve memory. Indeed, MEL's scientists have discovered that these animals are more anxious and display memory alterations.

The Company's scientists presented their findings in an article entitled "Behavioral Alterations Associated with Apoptosis and Down-regulation of Presenilin 1 in the Brains of p53 Deficient Mice" that appeared in the 5/9/00 issue of the Proceedings of the National Academy of Science, USA.

The content of this work is protected by a patent filed by Cabinet Regimbeau in Paris. Patent application 98/10076 entitled “Animal model presenting a memory deficiency and/or behavior trouble” and PCT patent application FR 99/01828 for Europe, Canada, Japan and the United States.